Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Commitment to partnership and joint innovation for cell and gene therapies
Hovione commitment to setting SBTs in line with the Paris Agreement
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.
Hovione is closer to its customers with a new website in Mandarin
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.